← All trials
NCT05239182
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- Feb 14, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 7
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KansasLead sponsor
- IncyteCollaborator
- University of KansasOverall official - principal investigator
- University of KansasReponsible party - principal investigator
- Actuate Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.